Samsung Bioepis and Teva Signed Biosimilar Agreement
The partnership covers six potential biosimilar candidates across the United States, Europe, and Canada.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you believe increasing the availability of biosimilar medicines will help lower overall healthcare costs?
Samsung Bioepis and Teva Pharmaceutical Industries have formed a global licensing agreement for six biosimilar candidates. The deal covers development and commercialization in the United States, Europe, and Canada.
Why it matters
This collaboration aims to increase patient access to biosimilar medicines by combining Samsung Bioepis's manufacturing expertise with Teva's global distribution network. The agreement strengthens an existing partnership that has already delivered products like EPYSQLI to the market.
The agreement encompasses six total biosimilar assets, including two confirmed candidates: SB41, referencing Fasenra, and SB44, referencing Ilaris. Samsung Bioepis maintains responsibility for the technical manufacturing and regulatory filing processes.
The players
Samsung Bioepis
A biopharmaceutical company focused on the development and manufacturing of high-quality biosimilar medicines.
Teva Pharmaceutical Industries
A global leader in the pharmaceutical sector known for its extensive portfolio of generic and specialty medicines.
The details
Samsung Bioepis will handle the development, manufacturing, and regulatory registration for the candidates, while Teva will spearhead commercial efforts. The companies also possess an option to extend this collaboration to four additional assets and new geographic territories.
Timeline
October 1, 2026: The companies announced the new biosimilar partnership agreement.
The Tech Race
This agreement builds upon the previous commercialization of EPYSQLI, signaling a strategic shift toward broad-scale pipeline development in the competitive biosimilar market. The move positions the companies to challenge major biologics by leveraging centralized manufacturing and localized sales.
Patients in the United States, Europe, and Canada may see increased availability of lower-cost biosimilar treatments for conditions currently managed by expensive biologics. The expansion of this partnership aims to streamline the supply chain to bring these medical alternatives to market more efficiently.
The takeaway
This partnership highlights how collaborative manufacturing and distribution models are essential for scaling biosimilar accessibility. It suggests a future where high-cost biologic therapies face increased competition through streamlined regulatory and commercial partnerships.
Further reading
Learn more about the latest innovations and market trends in Biotech.
Live Poll
Do you believe increasing the availability of biosimilar medicines will help lower overall healthcare costs?
